Jason Lief, Special Counsel, Cooley LLP to Speak at The Knowledge Group's Hatch-Waxman Litigation: Legal and Regulatory Updates in 2018
The Knowledge Group/The Knowledge Congress Live Webcast Series, the leading producer of regulatory focused webcasts, has announced today that Jason Lief, Special Counsel, Cooley LLP will speak at The Knowledge Group’s webcast entitled: “Hatch-Waxman Litigation: Legal and Regulatory Updates in 2018.” This event is scheduled for May 30, 2018 from 3:00 pm to 4:30 pm ET.
- (1888PressRelease) May 30, 2018 - The Knowledge Group/The Knowledge Congress Live Webcast Series, the leading producer of regulatory focused webcasts, has announced today that Jason Lief, Special Counsel, Cooley LLP will speak at The Knowledge Group’s webcast entitled: “Hatch-Waxman Litigation: Legal and Regulatory Updates in 2018.” This event is scheduled for May 30, 2018 from 3:00 pm to 4:30 pm ET.
For further details, please visit: https://www.theknowledgegroup.org/webcasts/hatch-waxman-litigation-2018/
About Jason Lief
Jason Lief is a patent litigator who focuses on pharmaceutical and Hatch-Waxman litigation. For more than two decades Jason has represented some of the world’s most renowned innovators in dozens of cases often involving billion-dollar products, establishing a winning track record and a reputation for courtroom excellence. Jason has litigated and tried dozens of Hatch-Waxman and other pharmaceutical patent cases before federal courts throughout the US, including cases involving Zantac®; Wellbutrin®; Wellbutrin SR®; Wellbutrin XL®; Ceftin®; Intuniv®; Vyvanse®; Oxtellar XR®; Angiomax® and Lialda®. In addition, Jason has litigated biotech, chemical and consumer products patent cases, as well as copyright, trademark and trade secret cases. He has argued before the US Court of Appeals for the Federal Circuit and also made appearances in foreign courts pursuant to the Hague Convention.
About Cooley LLP
Cooley has 900 lawyers across 12 offices in the United States, China and Europe. Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law. We have a fully integrated IP litigation, counseling and prosecution practice and are called on to litigate IP disputes involving core technologies, products and brands. Visit us as: www.cooley.com.
Website: https://www.cooley.com/
Abstract
Following the Supreme Court's decision in TC Heartland, LLC v. Kraft Foods Group Brands LLC and the U.S. Food and Drug Administration's (FDA) issuance of the Final Rule for the implementation of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, new and existing issues in the Hatch-Waxman litigation landscape are given increased attention. Counsel for Hatch-Waxman cases must understand these issues to best serve the interest of their clients.
In this LIVE Webcast, a panel of key thought leaders and professionals assembled by The Knowledge Group will discuss in-depth the legal and regulatory developments impacting the Hatch-Waxman litigation landscape. They will also provide the audience with practical strategies in bringing out the best in these lawsuits amidst these developments.
Key topics include:
• Hatch-Waxman Act: An Overview
• Impact of FDA Rule Changes
• TC Heartland's Impact on Hatch-Waxman
• Venue and Jurisdiction in personam
• Other Legal and Regulatory Updates
About The Knowledge Group/The Knowledge Congress Live Webcast Series
The Knowledge Group was established with the mission to produce unbiased, objective, and educational live webinars that examine industry trends and regulatory changes from a variety of different perspectives. The goal is to deliver a unique multilevel analysis of an important issue affecting business in a highly focused format. To contact or register for an event, please visit: http://theknowledgegroup.org/
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam